Differences in tumor biology and clinical outcomes by ER status in HER2+ breast cancer have been shown to exist, and HER2+ breast cancer is acknowledged to be heterogenous adding credence to prior epidemiological findings [10, 31, 32]. Here, ESR1 is linked to neoplasm.